Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Expanding Diagnostic Tools for iRBD Through Actigraphy-Based Classifiers
July 15th 2025Emmanuel During, MD, an associate professor of neurology at the Icahn School of Medicine at Mount Sinai, discussed the external validation of an actigraphy-based classifier for diagnosing iRBD and its implications for scalable neurodegenerative screening.
Advancing Research and Drug Development for Isolated RBD: Emmanuel During, MD
July 8th 2025The associate professor of neurology at the Icahn School of Medicine at Mount Sinai detailed how monitoring tools and neuroprotective approaches are evolving for iRBD as research intensifies on its link to Parkinsonian syndromes. [WATCH TIME: 4 minutes]
Predicting Amyloid Positivity with CARM: Clinical Insights from James Galvin, MD, MPH
July 7th 2025The professor of neurology at the Miami Miller School of Medicine discussed how the Cognivue Amyloid Risk Measure (CARM) may help predict amyloid presence and informs diagnosis, trial eligibility, and early treatment pathways.
Validating a Wearable-Based Classifier to Detect iRBD: Emmanuel During, MD
July 2nd 2025The associate professor of neurology at the Icahn School of Medicine at Mount Sinai explained how his team validated an iRBD actigraphy classifier across new devices and datasets to enhance early, scalable screening for neurodegenerative disease. [WATCH TIME: 5 minutes]